Mutations in the TP53 gene and protein expression of p53, MDM 2 and p21/WAF-1 in primary cervical carcinomas with no or low human papillomavirus load

British Journal of Cancer

Volumn 78, Issue 1, 1998, Pages 69-72

  Helland, A ^a   Karlsen, F ^a   Due, E U ^a   Holm, R ^a   Kristensen, G ^b   Borresen Dale A L ^a,c  

^a INSTITUTE OF CANCER RESEARCH   (Norway)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

^c UNIVERSITY OF OSLO   (Norway)

Author keywords

Human papillomavirus negative cervical carcinoma; p21 and MDM2 expression; p53; TP53 mutation

Indexed keywords

CELL PROTEIN; PROTEIN P21; PROTEIN P53; VIRUS PROTEIN;

ARTICLE; DENATURING GRADIENT GEL ELECTROPHORESIS; GENE MUTATION; GENE SEQUENCE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; NONHUMAN; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE; UTERINE CERVIX CARCINOMA; VIRUS LOAD; WART VIRUS;

EID: 0031833859     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1998.444     Document Type: Article

References (30)

1. Andersen TI and Børresen A-L (1995) Alterations of the TP53 gene as a potential prognostic marker in breast carcinomas. Advantages of using constant denaturant gel electrophoresis in mutation detection. Diagn Mol Pathol 4: 203-211
2. Bosch FX, Manos MM, Muñoz N, Sherman M, Jansen AM, Peto J, Schiffman MH, Moreno V, Kurman R and Shah KV (1995) Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. J Natl Cancer Inst 87: 796-802
3. Børresen A-L (1996) Constant denaturant gel electrophoresis (CDGE) in mutation screening. In Mutation screening. In Technologies for Detection of DNA Damage and Mutations, Pheifer GP (ed.), Chapter 20, pp. 267-279, Plenum Press: New York
4. Børresen A-L, Helland Å, Nesland J, Holm R, Trope C and Kaern J (1992). Papillomaviruses, p53 and cervical cancer. Lancet 339: 1350-1351
5. Busby-Earle RMC, Steel CM, Williams ARW, Cohen B and Bird CC (1994). p53 mutations in cervical carcinogenesis - low frequency and lack of correlation with human papillomavirus status. Br J Cancer 69: 732-737
6. Chen T-M, Chen C-A, Hsieh C-Y, Chang D-Y, Chen Y-H and Defendi V (1993) The state of p53 in primary human cervical carcinomas and its effects in human papillomavirus-immortalized human cervical cells. Oncogene 8: 1511-1518
7. Choo K-B and Chong KY (1993) Absence of mutation in the p53 and the retinoblastoma susceptibility genes in primary cervical carcinomas. Virology 193: 1042-1046
8. Crook T, Wrede D and Vousden KH (1991) p53 point mutation in HPV negative human cervical carcinoma cell lines. Oncogene 6: 873-875
9. De Roda Husman A-M, Walboomers JMM, van den Brule AJC, Meijer CJLM and Snijders PJF (1995) The use of general primers GP5 and GP6 elongated at their 3′ ends with adjacent highly conserved sequences improves human papillomavirus detection by PCR. J Gen Virol 76: 1057-1062
10. Durst M, Glitz D, Schneider A, zur Hausen H (1992) Human papillomavirus type 16 (HPV 16) gene expression and DNA replication in cervical neoplasia: analysis by in situ hybridization. Virology 189: 132-140
11. El-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parson R, Trent JM, Lin D, Mercer E, Kinzler KW and Vogelstein B (1993) WAFI, a potential mediator of p53 tumor suppression: Cell 75: 817-825
12. Fujita M, Inoue M, Tanizawa O, Iwamoto S and Enomoto T (1992) Alterations of the p53 gene in human primary cervical carcinomas with and without human papillomavirus infection. Cancer Res 52: 5323-5328
13. Helland Å, Holm R, Kristensen G, Kaern J, Karlsen F, Trope C, Nesland JM and Børresen A-L (1993) Genetic alterations of the TP53 gene, p53 protein expression and HPV infection in primary cervical carcinomas. J Pathol 171: 105-114
14. Ikenberg H, Matthay K, Schmitt B, Bauknecht T, Kiechle-Schwarz M, Göppinger A and Pfleiderer A (1995) p53 mutation and MDM2 amplification are rare even in human papillomavirus-negative cervical carcinomas. Cancer 76: 57-66
15. Iwasaka T, Oh-Uchida M, Matsuo N, Yokoyama M, Fukuda K, Hara K, Fukuyama K, Hori K and Sugimori H (1993) Correlation between HPV positivity and state of the p53 gene in cervical carcinoma cell lines. Gynecol Oncol 48: 104-109
16. Jenkins A, Kristiansen B-E, Ask E, Oskarsen B, Kristiansen E, Lindqvist B, Trope C and Kjørstad K (1991) Detection of genital papillomavirus types by polymerase chain reaction using common primers. Acta Pathol Microbiol Immunol Scand 99: 667-673
17. Jiko K, Tsuda H, Sato S, Hirohashi S (1994). Pathogenetic significance of p53 and c-Ki-Ras gene mutations and human papillomavirus integration in adenocarcinoma of the uterine cervix and the uterine isthmus. Int J Cancer 59: 601-606
18. Karlsen F, Kalantari M, Jenkins A, Pettersen E, Kristensen G, Holm R, Johansson B and Hagmar B (1996) Use of multiple PCR primer sets for optimal detection of human papillomavirus. J Clin Microbiol 34: 2095-2100
19. Kubbutat MHG, Jones SN and Vousden KH (1997) Regulation of the p53 stability by Mdm2. Nature 387: 299-303
20. Manos MMY, Ting DK, Wright AJ, Lewis TR, Broker TR and Wolinsky A (1989) The use of polymerase chain reaction amplification for detection of genital human papilloma virus. Cancer Cells 7: 209-214
21. Milde-Langosch K, Albrecht K, Joram S, Schlechte H, Giessing M and Löning T (1995) Presence and persistence of HPV infection and p53 mutation in cancer of the cervix uteri and the vulva. Int J Cancer 63: 639-645
22. Miwa K, Miyamoto S, Kato H, Imamura T, Nishida M, Yoshikawa Y, Nagata Y, Wake N (1995) The role of p53 inactivation in human cervical cell carcinoma development. Br J Cancer 71: 219-226
23. Paquette RL, Lee YY, Wilczynski SP, Karmakar A, Kizaki M, Miller CW and Koeffler HP (1993) Mutations of p53 and human papillomavirus infection in cervical carcinoma. Cancer 72: 1272-1280
24. Scheffner M, Werness BA, Huibregtse JM, Levine AJ and Howley PM (1990) The oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 63: 1129-1136
25. Scheffner M, Münger K, Byrne JC and Howley PM (1991) The state of the p53 and retinoblastoma genes in human cervical carcinoma cell lines. Proc Natl Acad Sci USA 88: 5523-5527
26. Sidransky D, Tokino T, Helzlsouer B, Zehnbauer B, Rausch G, Shelton B, Prestigiacomo L, Vogelstein B and Davidson N (1992) Inherited p53 gene mutations in breast cancer. Cancer Res 52: 2984-2986
27. Srivastava S, Tong YA, Devadas K, Zou ZQ, Chen Y, Pirollo KF and Chang EH (1992) Carcinogenesis 13: 1273-1275
28. Tieben LM, Schegget JT, Minnaar RP, Bouwes Bavinck JN, Berkhout RJM, Vermeer VJ, Jebbink MF and Smits HL (1993) Detection of cutaneous and genital HPV types in clinical samples by PCR using consensus primers. J Virol Methods 42: 265-280
29. Tsuda H and Hirohashi S (1992) Frequent occurence of the p53 gene mutations in uterine cancers at advanced clinical stage and with aggressive histological phenotypes. Jpn J Cancer Res 83: 1184-1191
30. Yaginuma Y and Westphal H (1991) Analyses of the p53 gene in human uterine carcinoma cell lines. Cancer Res 51: 6506-6509